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The transmembrane protein TIM-3 is a type I protein expressed by sub-types of lymphoid 
cells, such as lymphocytes Th1, Th17, Tc1, NK, as well as in myeloid cells. Scientific evi-
dence indicates that this molecule acts as a negative regulator of T lymphocyte activation 
and that its expression is modified in viral infections or autoimmune diseases. In addition 
to evidence from lymphoid cells, the function of TIM-3 has been investigated in myeloid 
cells, such as monocytes, macrophages, and dendritic cells (DC), where studies have 
demonstrated that it can regulate cytokine production, cell activation, and the capture 
of apoptotic bodies. Despite these advances, the function of TIM-3 in myeloid cells 
and the molecular mechanisms that this protein regulates are not yet fully understood. 
This review examines the most recent evidence concerning the function of TIM-3 when 
expressed in myeloid cells, primarily macrophages, and the potential impact of that 
function on the field of basic immunology.
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iNTRODUCTiON
The proteins of the TIM family (T cell immunoglobulin and mucin domain) are expressed on the 
surface of diverse cell types of the immune system (1). They were first described in mice T lympho-
cytes (TIM-1, TIM-2, TIM-3, and TIM-4) and next in humans (TIM-1, TIM-3, and TIM-4) (2–5). 
Homologs of TIM proteins have been identified in other species as well, including monkeys and 
rats (2, 6). These proteins can regulate diverse effectors pathways of the immune response. TIM-3 is 
expressed in CD4+ T cells that secrete interferon-gamma (IFN-γ), CD8+ T cells, dendritic cell (DC), 
and macrophages, among others. Also, it has been proposed as a regulator of the Th1 type immune 
response (7). Evidence gathered to date suggests both negative (inhibition) and positive (activation) 
regulatory functions on diverse components of the immune response. These data underline the 
Abbreviations: ARG-1, arginase 1; BAT-3, HLA-B 3-associated transcript; CD, cluster of differentiation; cDNA, complemen-
tary deoxyribonucleic acid; DC, dendritic cell; DNA, deoxyribonucleic acid; EAE, experimental autoimmune encephalitis; 
Gal-9, galectin 9; HMGB1, high mobility group box 1 protein; huHAVcr-1, human homolog of the receptor of the hepatitis 
A 1 virus; IFN-γ, gamma interferon; IgV, immunoglobulin domain; IL, interleukin; iNOS, inducible nitric oxide synthase; 
ITAM, tyrosine-based activation motif; LPS, lipopolysaccharide; M.tb, Mycobacterium tuberculosis; M-CSF, macrophage 
colony-stimulating factor; MMP-9, matrix metalloproteinase 9; NK, natural killer cell; PD-1, programed death receptor 
1; RNA, ribonucleic acid; siRNA, interference ribonucleic acid; STAT, signal transducer and transcription activator; TAM, 
tumor-associated macrophage; TB, tuberculosis; Tc, cytotoxic T lymphocyte; TGF-β, transforming growth factor beta; Th, 
T lymphocyte cooperator or collaborator; TIM-3, T cell molecule with immunoglobulin and mucin domain 3; TLR, toll-like 
receptor; TNF-α, tumor necrosis factor alpha; VEGF, vascular endothelial growth factor; VIH, human immunodeficiency virus.
2Ocaña-Guzman et al. Macrophages and TIM-3
Frontiers in Immunology | www.frontiersin.org June 2016 | Volume 7 | Article 229
importance of determining whether the function of TIM-3 differs 
in the diverse cell types in which it is expressed.
The first protein of this family discovered (TIM-1) was 
described as a marker of renal damage and associated with 
adhesion functions in a murine model (3, 4). The association 
of TIM proteins with immunological functions began to be 
deduced from a study that compared the presence of polymor-
phisms in BALB/C and DBA/2 mice by the genetic mapping 
of congenic animals, in order to identify the locus responsible 
for variations in susceptibility to asthma (5). That study 
confirmed the presence of the locus called T cell and airway 
phenotype regulator (Tapr) that groups a series of genes found 
in a region previously associated with susceptibility to asthma 
(5), which includes, among others, genes of the TIM family 
(5). Since then, the function of these proteins has been studied 
in several in vivo and in vitro experimental models to evaluate 
its participation during the immune response of autoimmune 
diseases, bacterial and viral infections, and pathologies with 
oncogenic origin.
STRUCTURe OF THe TiM PROTeiNS
In mice, the family of TIM proteins includes eight genes, of which 
only four codify for functional proteins (TIM-1 to TIM-4). In 
humans, three genes have been identified that codify for TIM-1, 
TIM-3, and TIM-4 (8). Each one of these genes codifies for a 
type I protein localized in the cell’s plasma membrane. The TIM-3 
protein is 281 amino acids in size, with a total homology of 77% 
with the murine protein (7). The structure of the TIM proteins 
consists of four well-defined regions.
 1. Variable immunoglobulin domain (IgV),
 2. Mucin domain,
 3. Transmembrane region, and
 4. Intracellular stem.
The IgV domain contains two anti-parallel chains, where four 
cysteines can be identified in the variable region of all members 
of this family, suggesting that they are highly conserved regions. 
Although it shares some characteristics with the IgV domains of 
a more conventional structure, the IgV domain of TIM-3 contains 
two disulfide bridges in the four cysteines conserved from the 
TIM proteins (9), a characteristic shared by the entire TIM family. 
In most IgV domains of diverse proteins, there are well-defined 
structures called CC′ loop and FG loop, named after the folded 
beta sheets that make up interactions established by the disulfide 
bonds. In the super-family of conventional immunoglobulins, 
the CC′ and FG loops are located at opposite ends of the IgV 
domain, at an approximate distance of 25  Å, but in TIM-1, 3, 
and 4 proteins, a distinct spatial arrangement has been identified 
due to the presence of disulfide bonds formed between the four 
cysteines, which re-orient the CC′ loop more proximal to the FG 
loop, creating a unique cleft in the IgV domain of the proteins 
of this family (9) (Figure 1). This characteristic cleft of the TIM 
proteins is stabilized by disulfide and hydrogen bonds (9). It is 
possible that this peculiar structure may modify the biological 
function of the IgV domain of TIM-3, though this has not yet been 
demonstrated. The two ligands known for TIM-3  –  galectin-9 
(Gal-9) and phosphatidylserine (PS) – bond to the protein’s IgV 
domain. Although there are glycosylation sites at the extracellular 
domain of TIM-3, it has been shown that only IgV glycosylation is 
required for Gal-9 binding (10). On the other hand, the PS bind-
ing to TIM-3 does not require additional glycosylations (9, 11).
The mucin domain varies considerably in length among dif-
ferent members of this family. TIM-3 is the molecule with the 
smallest domain (8). This region is especially rich in threonine, 
proline, and serine (9). TIM proteins cross the cell membrane by 
means of a tail embedded in the lipid bilayer. This tail is formed 
primarily of hydrophobic amino acids and penetrates into the 
interior of the cell with a cytoplasmic domain of ~42–77 amino 
acids in size. This is the most similar domain in humans and mice 
(8). Within the intracellular region of TIM-1 and TIM-3, there 
are phosphorylation sites, but in the former case, they are of two 
sub-types: one called TIM-1a that is expressed mainly in human 
liver cells and does not contain the amino acid sequence on which 
the kinase enzyme acts and the other, TIM-1b, is found primarily 
in human kidneys and conserves two threonine residues that 
make it susceptible to phosphorylation (8).
Based on the knowledge that TIM-2 transduces intracellular 
signals by phosphorylation of tyrosine residues, it was considered 
that this mechanism could also be present in TIM-3 (12). It has 
been demonstrated that the intracellular signaling of TIM-3 
begins after its interaction with Gal-9 and when the tyrosine 265 
(Y265) located at the cytoplasmic tail is phosphorylated by the 
interleukin inducible T-cell kinase (ITK) (13). Additionally, it has 
also been documented that the kinases Fyn and Lck can mediate a 
more efficient phosphorylation of TIM-3 (13). Finally, Rangachari 
et al. demonstrated that the Bat-3 protein (human leukocyte anti-
gen B-associated transcript 3) is associated with the intracellular 
portion of TIM-3 in T lymphocytes and Bat-3 recruits a kinase of 
the Src family (Lck) (14). Thus, determining whether the intracel-
lular signaling of TIM-3 in the macrophage involves Bat-3 and 
some kinase of the Src family will be fundamental as we strive to 
achieve a better understanding of the functioning of this protein. 
There is evidence to suggest that the Lck protein is not expressed 
in macrophages, but may express some isoform; therefore, the 
functioning of the TIM-3 receptor could differ in cells of myeloid 
origin. Conducting research in this area will allow us to learn more 
about the differences that exist in the function of TIM-3 between 
lymphocytes and myeloid cells. All these evidences allow us to 
consider that intracellular phosphorylation of TIM-3 is mediated 
by different kinases and with different levels of efficiency. This final 
regulation may have a direct impact on TIM-3 function when 
expressed by different cells.
TiM-3 AND iTS eXPReSSiON iN 
MACROPHAGeS
Although the TIM-3 protein was initially identified as a mem-
brane marker specific for Th1 and Tc1 (7) lymphocytes, its 
expression was soon confirmed in other cells (Table 1) (7, 15, 16). 
Today, we know that it is expressed in monocytes, macrophages, 
DC, NK cells, and even in a variety of cells in different types of 
tumors (3, 13–15, 17). Scientific findings suggest that TIM-3 and 
FiGURe 1 | Comparative schemes of the PD-1 (left panel) and TiM-3 (right panel) proteins showing the different conformation of the variable 
immunoglobulin domain (igv). In a conventional IgV domain like that of PD-1, the FG and CC′ loops are spatially distant (25 Å), while in the IgV domain of TIM-3, 
the distance between them is smaller due to the presence of disulfide bonds. Thus, a distinct spatial conformation is formed in TIM-3 compared to the other 
proteins that contain immunoglobulin domains (9, 17). [Glycosylation sites within the IgV domain (9) have been omitted to simplify.]
TABLe 1 | Functions of TiM-3 in the immune response.
Cell type Mechanism mediated or regulated by TiM-3 Reference
Macrophages–
monocytes
Capture and elimination of apoptotic bodies after 
phosphatidylserine union
(29, 31)
Inhibition of the TLR-mediated activation (34, 49)
Increases the production of IL-12, IL-6, and IL-10 (34, 35)
High TIM-3 level of expression inhibits IL-12 production
Antigen cross-presentation (29)
Production of IL-1b dependent on caspase-1 
activation. Elimination of intracellular M.tb
(23, 24)
Dendritic cells Inhibits the immune response to damage signals 
as nucleic acids and HMGB-1 protein
(16)
Capture and elimination of apoptotic bodies and 
antigen presentation
(29)
NK cells Increased frequency of TIM-3+ cells induces 
immune tolerance and reduces inflammatory 
pathology in mice infected with Toxoplasma gondii
(48)
HeLa cells Promotes metastasis (37)
CD, cluster of differentiation; DC, dendritic cell; HMGB1, high mobility group box 1 
protein; IL, interleukin; MMP-9, matrix metalloproteinase 9; M.tb, Mycobacterium 
tuberculosis; NK, natural killer cell; TAM, tumor-associated macrophage; TIM-3, 
T cell molecule with immunoglobulin and mucin domain 3; TLR, toll-like receptor, 
VEGF, vascular endothelial growth factor.
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its ligand Gal-9 function as a negative regulatory pathway in T cell 
activation. The failure, or absence, of this pathway has been asso-
ciated with the development of autoimmune diseases (18–22); 
however, it is important to determine its function in other cells, 
such as monocytes or macrophages, since some reports suggest 
that TIM-3 can function as a molecule that participates in cell 
activation and the elimination of different pathogens (23, 24).
TiM-3 ALLOwS ReCOGNiTiON AND 
PHAGOCYTOSiS OF APOPTOTiC 
BODieS viA PHOSPHATiDYLSeRiNe
Efferocytosis or elimination of apoptotic cells and bodies is a 
physiologic and vital mechanism that avoids tissue inflamma-
tion and autoimmune responses. It was first described by de 
Cathelineau and Henson (25) to differentiate between macro-
pinocytosis and opsonization. Efferocytosis is a mechanism 
that maintains immune tolerance while allowing development 
of antibacterial immune responses (26, 27). Recent evidence 
suggests that TIM proteins play a role in efferocytosis. The recep-
tors utilized by phagocytic cells to internalize the detritus of 
4Ocaña-Guzman et al. Macrophages and TIM-3
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apoptotic cells include some members of the TIM family. TIM-1 
and 4 were the first proteins of this family in which the bonding 
site to PS was identified. PS is a phospholipid that translocates 
to the external face of the plasma membrane of apoptotic cells, 
and the principal “eat me” signal that triggers their capture and 
elimination (28). This early evidence suggested that TIM-3 
could bond to phospholipids. Since then, crystallography stud-
ies have proven that TIM-3 does indeed bond to PS via an FG 
loop located in the IgV domain (9, 29). This mechanism was 
identified initially in CD8+ DC and macrophages in an in vitro 
model, and its presence was confirmed later in a murine model. 
Since PS is the principle signal for the phagocytosis of apoptotic 
bodies or cells, when recognition of this TIM-3-mediated phos-
pholipid is blocked with specific antibodies apoptotic bodies are 
not removed, and this can induce immunological abnormalities, 
such as the generation of autoantibodies (29, 30). This scientific 
evidence agrees with the results obtained on lymphocytes upon 
evaluating the function of TIM-3 in autoimmune-type diseases, 
such as experimental autoimmune encephalitis (EAE) and 
multiple sclerosis, where research has documented that reduc-
ing TIM-3 expression is associated with an aggravated state 
of the disease and a high frequency of autoreactive cells (18). 
While these studies support the function of TIM-3 promoting 
immunological tolerance, they also raise new questions about 
this protein. For example, it is necessary to clarify why CD8+ DC 
can capture, phagocyte, and favor antigen presentation, while 
CD8− DC do not perform these functions although they also 
express TIM-3 and are capable of responding to the presence 
of apoptotic bodies by producing inflammatory cytokines (29). 
Studies have also confirmed that allelic variants of TIM-3, that 
differ in seven amino acids in the FG loop and come from two 
strains of mice (BALB/c and HBA), possess distinct abilities to 
interact with PS (31). It has been demonstrated that phagocytic 
cells from the BALB/c strain bond to, and phagocyte, apoptotic 
cells by means of TIM-3, while the cells that express the HBA 
variant of TIM-3 can form complexes with PS, but are incapable 
of internalizing apoptotic bodies (31). But these findings are not 
enough to clarify the differences in the function of TIM-3 in the 
different cell types that express it. For example, TIM-3 expression 
has been demonstrated on peritoneal exudative macrophages, 
but not on peritoneal resident macrophages. However, TIM-4 is 
highly expressed on peritoneal resident macrophages and binds 
to PS on apoptotic cells from the peritoneal cavity. The different 
expression profile and function of TIM-3 compared with TIM-4 
is not redundant and is important for maintaining immune 
tolerance. These results may indicate that different macrophage 
subsets could use different molecules (TIM-3 or TIM-4) to 
recognize PS (29).
Available evidence seems to suggest that the function of TIM-3 
changes depending on the type of cell in which it is expressed but 
that the level of expression seems to contribute as well; for exam-
ple, CD8+ DC have a level of expression of TIM-3 three times 
greater than CD8− DC (29). Moreover, phagocytic activity of 
each cell subset is the result of various considerations as the level 
of expression of the phagocytic receptors, the microenvironment 
where the cells are located as well as their cytoskeletal architec-
ture. For example, when TIM-3 is expressed by lymphocytes (32), 
these cells do not recognize apoptotic cells or bodies; however, 
macrophages or DCs expressing TIM-3 do phagocyte. For this 
reason, it is important to conduct functional studies comparing 
TIM-3+ vs. TIM-3− cells and identify the signaling pathways 
that define the role of this protein in each cell type.
TiM-3 ReGULATeS THe PRODUCTiON 
AND ReLeASe OF CYTOKiNeS iN 
MONOCYTeS AND MACROPHAGeS
It has been demonstrated that TIM-3 expression is dynamic, 
regulates the activation of diverse cells, and has the capacity 
to induce the production of distinct cytokines. This has been 
shown for monocytes and macrophages that express TIM-3 in 
a constant manner (Figure 2). In both the THP-1 cell line and 
CD14+ cells purified from human peripheral blood, studies have 
confirmed that monocytes/macrophages in a quiescent state have 
a high expression of TIM-3 with low cytokine production. When 
stimulated in  vitro with LPS and the R848 compound (ligands 
for TLR4 and TLR7/8, respectively), these macrophages reduce 
the expression of TIM-3 in a concentration-dependent manner, 
while also beginning to produce IL-12 after stimulus reception 
(33). Blocking TIM-3 with monoclonal antibodies and posterior 
stimulation with TLR results in an increase in the production 
of IL-12, IL-6, and IL-10, but a reduced expression of PD-1, an 
inhibitor molecule of the T cell function. However, experiments 
made on THP-1 macrophages demonstrated that after silencing 
TIM-3 expression with siRNA, the production of IL-12 and 
IL-10 was increased (33, 34). These findings confirm that IL-12 
expression is negatively regulated by TIM-3, contrary to what 
occurs with PD-1, which increases together with TIM-3. Another 
important finding is that when TIM-3 is expressed on other cells 
(trans) or on the macrophage itself (cis), the association of TIM-3 
with its ligand, Gal-9, has a distinct effect as a regulator of TLR-
mediated activation (35). For example, the trans association of 
TIM-3 and Gal-9 negatively regulates TLR signaling, leading to 
an IL-12 reduction, increase in the IL-23 production, decrease 
in the phosphorylation of STAT-1, and/or activation of STAT-3. 
Meanwhile, the association in cis favors the correct TLR signaling, 
and it has been demonstrated that expression of Gal-9 increases 
through this mechanism (35).
TiM-3 iN MACROPHAGeS AND CANCeR
Unlike the negative regulator PD-1, which has been proposed 
as a therapeutic target in different types of cancer, the function 
of TIM-3 in cancer has just begun to be studied, so we know 
very little about its role in this pathology. However, the fact that 
its function and changes in the profile of cellular expression in 
pathological states is similar to those of PD-1 suggests that its 
function in the tumor microenvironment should be initially 
evaluated in the same context. We know that TIM-3 expression 
is not restricted to mononuclear cells, because it has also been 
detected in cancer cells. TIM-3 can be expressed in distinct types 
of cancer cells, including myeloid leukemia, sarcoma, gastric, 
cervical and pulmonary cancer, and osteosarcoma, among others 
FiGURe 2 | Potential role of TiM-3 on macrophages. (A) Macrophages with high expression of TIM-3 do not produce cytokines, favoring immune tolerance and 
reduce TLR activation. In the presence of the TLR ligands, LPS and R848, macrophage activation reduces expression of TIM-3 and lessens the regulatory effect 
mediated by this molecule, allowing correct activation and the consequent production of cytokines. (B) By silencing the expression of TIM-3 with siRNA or blocking 
antibodies, it is possible to induce correct macrophage activation similar to that observed on T cells.
5
Ocaña-Guzman et al. Macrophages and TIM-3
Frontiers in Immunology | www.frontiersin.org June 2016 | Volume 7 | Article 229
(36–39). In many of these types of cancer, the increased expres-
sion of TIM-3 has been associated with disease progression and 
shorter survival.
In T lymphocytes, it has been documented that the interaction 
of TIM-3 with Gal-9 inhibits cell activation and induces apop-
tosis via a mechanism that involves calpain and caspase-1 (40). 
Hence, the activity of the T lymphocytes could modify the tumor 
microenvironment, but how does TIM-3 participate in cancer 
progression? and what is its role in the tumor microenvironment 
when this molecule is expressed in macrophages and DC? These 
issues remain to be clarified. With respect to the innate immune 
system, studies have been conducted with distinct types of cancer 
to analyze the role of TIM-3 as a negative regulator of the func-
tion of T lymphocyte-mediated adaptive immunity and innate 
response when this molecule is expressed in macrophages and 
DC. One murine model of hepatic cancer documented an increase 
in TIM-3 expression in peripheral blood monocytes and tumor-
associated macrophages (TAMs), a finding that was positively 
correlated with disease progression (41). TAMs are characterized 
by presenting a phenotype denominated M2, characterized by the 
expression of CD163, CD206, Arg-1, and IL-10 (Figure 3) (41). 
Scientific evidence suggests that this phenotype, together with the 
increase in the expression of TIM-3, are induced by the TGF-β 
(41) and other cytokines, such as IL-4, IL-10, IL-13, and M-CSF 
found in the tumor microenvironment [reviewed by Allavena 
et al. (42)], which favor the alternative activation of macrophages. 
It is feasible that the M1 type macrophages that are activated 
by IFN-γ and that perform innate functions as phagocytosis, 
FiGURe 3 | TiM-3+ macrophages and its role in cancer progression. The M1 macrophages recruited to eliminate cancer cells have a low expression of TIM-3 
and perform diverse functions, such as phagocytosis, presentation of antigens, and production of pro-inflammatory cytokines, such as IFN-γ, TNF-α, and IL-12. 
When cancer cells and lymphocytes release anti-inflammatory cytokines into the environment such as IL-4 and TGF-β, they induce a change in the macrophages 
toward a regulator or tolerogenic profile (M2), accompanied by an increase in TIM-3 expression and in the expression of the specific markers of the M2 phenotype, 
such as DC 163 and DC 206, among others (41, 50, 51).
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promoting antitumor responses, and eliminating pathogens and 
transformed cells, could re-direct their M1 phenotype to the 
M2 phenotype, since they lose or reduce many of the protective 
functions in cancer, thus promoting tumor development and 
progression (41). These events are enabled by the characteristic 
plasticity of macrophages that – unlike lymphocytes which are 
polarized toward one of the known effector profile and suffer 
significant modifications at the level of the chromatin – show a 
genetic profile that changes depending on the type, concentra-
tion, and time of exposure to diverse stimuli (43, 44).
Other mechanisms that may favor tumor development 
involve exhausted T lymphocytes and DC. There is evidence that 
in  vitro interaction between monocytes and macrophages with 
autologous T lymphocytes with senescent phenotype induces 
higher production of pro-inflammatory cytokines, such as TNF-
α, IL-1b, and IL-6, as well as a greater production of angiogenic 
molecules, such as VEGF-α, MMP9, and IL-8, compared to 
monocytes cocultivated with control cells (45). TIM-3 can also 
favor the development of metastasis through a still unknown 
mechanism. For example, it has been reported that the HeLa cell 
line reduces the capacity for metastasis when TIM-3 is silenced 
by antisense cDNA (37).
In summary, TIM-3 participates in diverse suppressor pathways 
of the antitumor response in both myeloid cells and lymphocytes. 
As in the case of infectious diseases, it has been documented that 
simultaneous blocking of TIM-3 and PD-1 is more efficient in 
restoring the functionality of exhausted lymphocytes (46) and 
perhaps also in counteracting some inhibitory molecules in the 
macrophages and DC. It is possible that in macrophages, TIM-3 
functions as a receptor that, upon being treated with antibodies 
or agonist molecules, induces a more efficient immunological 
response due to an increase of the inflammatory response, similar 
to that observed in T lymphocytes when treated with anti-PD-1 
and anti-TIM-3 antibodies.
TiM-3 ReGULATeS THe iMMUNe 
ReSPONSe iN iNFeCTiOUS DiSeASeS
The innate immune response to bacterial and viral infections 
is one of the most important mechanisms for controlling the 
pathogens that invade organisms every day. TIM-3 participates 
significantly in the response to these pathogens, since we know 
that it can regulate the activation of macrophages and the effec-
tors function of these cells. Chronic bacterial infections like that 
of the intracellular pathogen Mycobacterium tuberculosis (M.tb) 
require a highly efficient Th1-type response; however, M.tb has 
developed diverse evasion strategies that allow it to survive the 
macrophage’s elimination systems, which are generally activated 
by IFN-γ produced by T lymphocytes with the Th1 profile. In 
an experimental model of in vitro infection with M.tb (H37Rv) 
performed in 2010, Jayaraman et  al. demonstrated that when 
peritoneal macrophages were infected with M.tb (in the absence 
of T lymphocytes) and treated with TIM-3 in the form of a fusion 
protein, which is composed of the immunoglobulin V portion of 
mouse TIM-3 fused with the human IgG1 Fc tail to form the solu-
ble TIM-3–Ig fusion protein, this protein limited bacterial growth 
through a mechanism that involved caspase-1-dependent IL-1b 
production (24). Blocking the activation of caspase-1, or treat-
ment with IL-1b-blocking antibodies, eliminated the effect of the 
treatment with the TIM-3 fusion protein (24). This phenomenon 
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has also been identified in human macrophages (23) infected 
with M.tb-H37Rv; moreover, studies have confirmed that IL-1b is 
the principal soluble factor that mediates inhibition of the growth 
of M.tb (47).
Another murine model, this one with infection by Toxoplasma 
gondii, an intracellular parasite that induces a Th1-type response, 
identified that mice of the C57BL/6 strain (susceptible) have a lower 
frequency of TIM-3+ immune cells in the spleen and mesenteric 
lymphatic nodes (NK, CD3+, CD11b, and CD11c+) compared 
to resistant BALB/c mice (48). The C57BL/6 mice developed an 
increased inflammatory condition mediated primarily by IFN-γ 
that induced extensive tissue damage in the small intestine with 
symptoms similar to Crohn’s disease (48). In contrast, the BALB/c 
mice that expressed a higher frequency of TIM-3+ cells did not 
develop this type of damage in the small intestine. These results 
suggest that TIM-3 functions as a molecule that favors tolerance 
by preventing an exacerbated inflammatory response in diverse 
tissues. One of the mechanisms by which TIM-3 can promote 
immunological tolerance in cells of the innate immune system 
consists in negatively regulating the activation induced by TLR 
signaling (35). This mechanism of negative regulation of activation 
in cells of the immune system that expresses TIM-3 is achieved 
by inhibiting the NF-Kb transcription factor, thus blocking the 
TLR-mediated response (49). Research has also documented a 
reduction in the release of pro-inflammatory cytokines, such as 
IFN-γ and IL-12, in macrophages with higher TIM-3 expression, 
compared to macrophages with a low expression of this molecule 
(33, 35). Finally, it has been demonstrated that the blocking or 
silencing of TIM-3 favors the development of sepsis, a severe 
inflammatory condition with a high mortality rate (49).
This evidence leads us to suggest that the TIM-3 molecule may 
play a dual role, since it participates in the activation of infected 
macrophages by inducing IL-1b-dependent bacteriostatic and 
bactericidal mechanisms. Also, when expressed in T lympho-
cytes, TIM-3 can negatively regulate the Th1 immune response. 
It is not yet possible to clarify the factors that produce these 
apparently contradictory findings and the possibility exists that 
the mechanisms induced by TIM-3 could occur simultaneously. 
The level of TIM-3 expression may be an important factor that 
affects the results and function of the TIM-3-dependent pathway. 
No simultaneous or comparative studies have yet been conducted 
to analyze the role of TIM-3 in macrophages and other cells of 
the innate immune system in the context of bacterial infections.
CONCLUSiON
Since the discovery of the TIM-3 molecule, numerous studies 
performed have made it possible to determine some aspects of 
the functioning of this molecule. At present, TIM-3 is considered 
an inhibitory molecule of the activation of diverse cells, or an 
immune repressor system. On the other hand, there is evidence 
that TIM-3 can favor the activation of some mechanisms of the 
immune response, as reported for macrophages. Although these 
findings seem contradictory, one could propose that the level of 
TIM-3 expression is an important factor that must be considered, 
since studies have shown that a reduction in the level of expres-
sion of TIM-3 favors the production of IL-12 and the activation of 
monocytes and macrophages (33). Although research has shown 
that the union of Gal-9 with TIM-3 induces activation of caspase-1 
and the posterior release of IL-1b, we do not yet know whether 
this mechanism is reproduced in the diverse sub-populations 
of macrophages, or even monocytes, since TIM-3 expression is 
dynamic and there are antecedents indicating that high expres-
sion of this molecule produces a state of tolerance or anergy to 
diverse antigenic stimuli. We require studies designed to evaluate 
the mechanisms of activation of phagocytic cells that take into 
account the level of expression and signaling of TIM-3. Finally, 
no one has yet demonstrated that TIM-3 is associated with the 
Bat-3 (14) protein in macrophages and DCs nor its interaction 
with the Lck protein, a very important kinase for the activation 
of transcription factors such as NF-kb. Analyzing and clarifying 
these issues will provide a broader perspective on the functions 
of TIM-3 and its role in myeloid cells. Such research is important 
because this field of study is lagging slightly behind analyses of the 
TIM-3 molecule in lymphoid cells.
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